» Articles » PMID: 29976231

Hydroxychloroquine Prescription Trends and Predictors for Excess Dosing Per Recent Ophthalmology Guidelines

Abstract

Background: Hydroxychloroquine (HCQ) retinopathy may be more common than previously recognized; recent ophthalmology guidelines have revised recommendations from ideal body weight (IBW)-based dosing to actual body weight (ABW)-based dosing. However, contemporary HCQ prescribing trends in the UK remain unknown.

Methods: We examined a UK general population database to investigate HCQ dosing between 2007 and 2016. We studied trends of excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW) and determined their independent predictors using multivariable logistic regression analyses.

Results: Among 20,933 new HCQ users (78% female), the proportions of initial HCQ excess dosing declined from 40% to 36% using IBW and 38% to 30% using ABW, between 2007 and 2016. Among these, 47% of women were excess-dosed (multivariable OR 12.52; 95% CI 10.99-14.26) using IBW and 38% (multivariable OR 1.98; 95% CI,1.81-2.15) using ABW. Applying IBW, 37% of normal and 44% of obese patients were excess-dosed; however, applying ABW, 53% of normal and 10% of obese patients were excess-dosed (multivariable ORs = 1.61 and 0.1 (reference = normal); both p < 0.01). Long-term HCQ users showed similar excess dosing.

Conclusion: A substantial proportion of HCQ users in the UK, particularly women, may have excess HCQ dosing per the previous or recent weight-based guidelines despite a modest decline in recent years. Over half of normal-BMI individuals were excess-dosed per the latest guidelines. This implies the potential need to reduce dosing for many patients but also calls for further research to establish unifying evidence-based safe and effective dosing strategies.

Citing Articles

Novel electroretinography devices to detect hydroxychloroquine retinopathy: study protocol for a diagnostic accuracy and feasibility study.

Lee C, Wafa H, Murphy G, Galloway J, Mahroo O, Jackson T BMJ Open Ophthalmol. 2024; 9(1.

PMID: 39719323 PMC: 11683940. DOI: 10.1136/bmjophth-2024-001898.


How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.

Fairley J, Nikpour M, Mack H, Brosnan M, Saracino A, Pellegrini M Intern Med J. 2022; 53(3):311-317.

PMID: 35969110 PMC: 10947006. DOI: 10.1111/imj.15908.


Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-19.

Shabani M, Totonchi M, Rezaeimirghaed O, Gachkar L, Hajiesmaeili M, Khoshkar A Pulm Pharmacol Ther. 2021; 70:102069.

PMID: 34389507 PMC: 8353977. DOI: 10.1016/j.pupt.2021.102069.


Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Systemic Lupus Erythematosus and Rheumatoid Arthritis: Results of a Quality Improvement Initiative.

Skorupa T, Shmerling R ACR Open Rheumatol. 2021; 3(10):733-737.

PMID: 34363746 PMC: 8516102. DOI: 10.1002/acr2.11320.


Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications.

Kumar R, Sharma A, Srivastava J, Siddiqui M, Uddin M, Aleya L Environ Sci Pollut Res Int. 2021; 28(30):40431-40444.

PMID: 33447984 PMC: 7808930. DOI: 10.1007/s11356-020-12200-1.


References
1.
Marmor M, Kellner U, Lai T, Melles R, Mieler W . Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016; 123(6):1386-94. DOI: 10.1016/j.ophtha.2016.01.058. View

2.
Petri M . Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2010; 13(1):77-80. DOI: 10.1007/s11926-010-0141-y. View

3.
Gonzalez-Suarez M, Contreras G . Lower kidney allograft survival in African-Americans compared to Hispanic-Americans with lupus. Lupus. 2017; 26(12):1269-1277. DOI: 10.1177/0961203317699287. View

4.
ODell J, Mikuls T, Taylor T, Ahluwalia V, Brophy M, Warren S . Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013; 369(4):307-18. DOI: 10.1056/NEJMoa1303006. View

5.
Bertsias G, Ioannidis J, Boletis J, Bombardieri S, Cervera R, Dostal C . EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2007; 67(2):195-205. DOI: 10.1136/ard.2007.070367. View